The lab draw you've been waiting months for — happening right now.
Gauge is a wrist-worn biosensor that tracks visceral fat shifts, metabolic rate, and inflammatory markers continuously — replacing quarterly lab draws with a stream of data clinicians and patients can act on today.
Patient Dashboard
Day 212 on Monitoring
Visceral Fat Index
Resting Metabolic Rate
1,847 kcal/day ↑ 214 from baseline
"My surgeon saw the inflammation spike before I felt it."
Marcus R., 47
Post-bariatric · GLP-1 protocol · Month 7
"Weekly visceral fat data changed how I manage my post-op patients. I used to wait for the 90-day follow-up to understand whether body composition was shifting. Now I'm making protocol adjustments at week three — before complications have a chance to develop."
Dr. Anita Krishnamurthy
MD, FACS — Bariatric & Metabolic Surgery
Northwestern Medicine · Bariatric Surgery · 18 years
How Gauge Reads Your Tissue
Multi-frequency electrical signals pass through tissue layers, returning fat, lean mass, and fluid data at clinical resolution — continuously.
Outer Housing
Medical-grade titanium
Optical Array
SpO₂ + photoplethysmography
BIS Electrode Grid
256-point impedance mapping
Signal Processor
On-device ML inference
Managing a post-bariatric panel?
See how Gauge integrates with your existing surgical workflow.
Live Patient Panel
Inflammatory Marker Trends
CRP-Proxy Index
↓ 71% over 12 weeksJames T., 54
Stable
Patricia W., 61
Alert
Ravi K., 48
Improving
CRP-proxy correlates r=0.84 with lab HbA1c in the Gauge METRO-2 trial (n=312).
"I manage 340 patients with metabolic syndrome. Before Gauge, my view into each patient's inflammatory trajectory was a point-in-time lab value every 90 days. Now I have a continuous signal. The CRP-proxy correlation with our lab HbA1c is 0.84 — that's clinical-grade resolution in a wearable."
Dr. Tobias Wernecke
MD, PhD — Endocrinology & Metabolism
UCSF Medical Center · Metabolic Syndrome · 22 years
Running a large endocrinology panel?
Gauge integrates with Epic and Cerner — no new workflow overhead.
"Patients on GLP-1 agonists twelve months in are asking the right question: is my body composition actually changing, or just my weight? The scale is a crude proxy. Gauge gives them — and their care team — the visceral fat index, lean mass trajectory, and metabolic rate in a single wrist-worn device. That specificity is what changes behavior."
Dr. Simone Okafor
MD, MPH — Obesity Medicine & GLP-1 Research
Brigham and Women's Hospital · Obesity Medicine · 14 years
Body Composition Shift
Beyond what the scale shows
Visceral Fat (L)
-44.7%Lean Mass
+8.9%Resting Met. Rate
+30.1%Visceral Inflam. Score
-72.1%Scale weight change: −6.2 kg
Scale weight alone missed 83% of the metabolic improvement Gauge recorded.
Not ready to commit? Read the evidence first.
The Gauge Efficacy Summary covers METRO-2 trial methodology and outcomes.
Clinical Evidence — METRO-2 Trial, 2025
0+
Patients monitored
across active trials
0
Clinical sites
US & EU
0%
Sensor uptime
90-day wear period
0
METRO-2 trial participants
peer-reviewed cohort
Five specialists just made the case.The data made it clearer.
Gauge is accepting applications from bariatric surgery practices, endocrinology panels, and GLP-1 program coordinators. Spots in the 2026 cohort are limited to 40 sites.
HIPAA compliant · IRB-approved protocols · No obligation